Ezetimibe is a low-cost, once-daily oral medication that lowers "bad" cholesterol by blocking its absorption in the gut, a mechanism separate from liver-acting cholesterol drugs. Alone it produces a moderate drop; added to a liver-acting drug it lowers cholesterol further and modestly reduces heart attacks and strokes in higher-risk people. It is exceptionally well tolerated. (Full Review)

Protocol

Dose

10 mg once daily

Single approved dose; no titration required

Timing

Any time of day

With or without food; consistency matters more than timing

Regimen

Alone or added to a statin

Add-on to a maximally tolerated statin, or a moderate statin plus ezetimibe together (combination-first)

Time to effect

Onset

~2 weeks

LDL cholesterol begins falling

Full effect

4–6 weeks

Usual window for a follow-up lipid panel

Benefits

High: LDL cholesterol lowering; fewer cardiovascular events as add-on to statins

Medium: apoB and non-HDL cholesterol reduction; LDL lowering in statin-intolerant individuals

Low: Coronary plaque stabilization; improvement in fatty liver markers

Speculative: Reduced dementia risk; anti-inflammatory effect beyond LDL

Contraindications

Known hypersensitivity to ezetimibe

Active liver disease (with statin combination)

Pregnancy and breastfeeding (with statin combination)

Moderate-to-severe hepatic impairment, Child-Pugh B or C (monotherapy)

Key Interactions

Statins (atorvastatin, rosuvastatin, simvastatin)

Bile acid sequestrants (cholestyramine, colestipol, colesevelam)

Cyclosporine

Fibrates (gemfibrozil, fenofibrate)

Risk & Side Effects

High: Gastrointestinal effects

Medium: Muscle pain; elevated liver enzymes

Low: Myopathy and rhabdomyolysis; gallstones; hypersensitivity reactions

Speculative: Pancreatitis; thrombocytopenia and other rare blood effects; cancer signal (conflicted)

Monitoring

Marker	Target	Why
LDL cholesterol	<70 mg/dL (higher-risk); <55 mg/dL (very-high-risk)	Primary target of therapy
Apolipoprotein B (apoB)	<80 mg/dL; <65 mg/dL (high-risk)	Counts artery-clogging particles; more complete than LDL alone
Non-HDL cholesterol	~30 mg/dL above the LDL target	Captures all atherogenic particles including remnants
Liver enzymes (ALT/AST)	Within normal laboratory limits	Detects the uncommon transaminase rise, mainly in statin combination
Lipoprotein(a) [Lp(a)]	<75 nmol/L (or <30 mg/dL)	Inherited, especially artery-damaging particle that refines risk
Creatine kinase (CK)	Within normal limits	Screens for muscle injury if symptoms arise

Cadence: Lipid panel and apoB at ~4–6 weeks, then every 6–12 months once stable; liver enzymes at baseline and as clinically indicated with a statin

Qualitative Assessment

Muscle comfort: absence of new or unusual muscle aches or weakness, particularly when combined with a statin
Digestive comfort: tolerability without persistent diarrhea or abdominal discomfort
Energy and general well-being: no new fatigue attributable to the medication
Adherence confidence: ability to maintain consistent daily dosing

Ezetimibe to Lower LDL

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment